Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Angiotensin 1/2 (2-7): Novel Insights into RAS Signaling ...

    2026-02-20

    Angiotensin 1/2 (2-7): Novel Insights into RAS Signaling and Viral Pathogenesis

    Introduction

    The renin-angiotensin system (RAS) orchestrates cardiovascular homeostasis through a network of peptides, enzymes, and receptors, with angiotensin-derived fragments acting as fine-tuned regulators. Among these, Angiotensin 1/2 (2-7) (sequence: ARG-VAL-TYR-ILE-HIS-PRO) has emerged as a structurally distinctive and functionally versatile peptide. While prior literature has focused on this fragment’s role in blood pressure regulation and RAS modeling, recent findings illuminate its deeper mechanistic involvement in both cardiovascular and viral pathobiology. This article provides an in-depth, mechanism-centric perspective, elucidating the unique biochemical properties and translational potential of Angiotensin 1/2 (2-7) in advanced research contexts.

    Biogenesis and Structural Characteristics

    Enzymatic Origins in the Renin-Angiotensin Signaling Pathway

    Angiotensin 1/2 (2-7) is generated through a series of precise proteolytic cleavages within the RAS. Renin initiates the cascade by acting on angiotensinogen to produce angiotensin I (1–10), which is then converted by angiotensin-converting enzyme (ACE) into angiotensin II (1–8). Further enzymatic processing yields shorter fragments, including Angiotensin 1/2 (2-7), comprising amino acids 2–7 of the parent peptide. This renin-angiotensin system peptide fragment (C37H57N11O8, MW 783.92) retains the critical ARG-VAL-TYR-ILE-HIS-PRO motif, endowing it with specific biological activities distinct from its longer precursors.

    Physical and Chemical Properties

    Supplied as a high-purity (99.80%, HPLC and MS validated) solid, Angiotensin 1/2 (2-7) exhibits robust solubility: ≥2.78 mg/mL in ethanol, ≥46.6 mg/mL in water, and ≥78.4 mg/mL in DMSO. For optimal stability, storage at -20°C is recommended, and solutions should be used short-term to preserve integrity. These properties facilitate reproducibility and adaptability in complex experimental workflows, making it a reliable choice for high-sensitivity research applications.

    Mechanism of Action: Beyond Canonical Blood Pressure Regulation

    Vasoconstrictor Activity and Aldosterone Stimulation

    Angiotensin 1/2 (2-7) acts as a vasoconstrictor peptide, modulating vascular tone and stimulating aldosterone release from the adrenal cortex. Through this pathway, it promotes sodium retention in the distal nephron, contributing to the fine regulation of extracellular fluid volume and arterial pressure. While these functions mirror those of longer angiotensin peptides, the unique N-terminal truncation of Angiotensin 1/2 (2-7) confers subtle differences in receptor affinity and downstream signaling, offering nuanced tools for blood pressure regulation research and the dissection of aldosterone-mediated effects.

    Interaction with Angiotensin II Receptors

    Angiotensin II exerts its classical effects primarily through AT1R and AT2R, two G protein-coupled receptors. Notably, N-terminal deletions, such as those represented by Angiotensin 1/2 (2-7), have been shown to modify receptor specificity and signal transduction. Such fragments may retain or even augment select functional properties, as demonstrated in recent receptor-binding assays. This provides a unique opportunity to isolate and interrogate specific aspects of the renin-angiotensin signaling pathway in both health and disease models.

    Emerging Role in Viral Pathogenesis: SARS-CoV-2

    Recent breakthroughs have extended the relevance of angiotensin fragments to viral disease mechanisms. In a seminal study (Oliveira et al., 2025), naturally occurring angiotensin peptides—including short N-terminal fragments analogous to Angiotensin 1/2 (2-7)—were found to enhance the binding of the SARS-CoV-2 spike protein to alternative host receptors such as AXL. While the classical focus has been on ACE2-mediated viral entry, this research highlights that short RAS peptides can potentiate spike–AXL interactions, potentially amplifying viral infectivity in tissues with low ACE2 expression. Modifications to the tyrosine residue within the peptide core (a key feature of the ARG-VAL-TYR-ILE-HIS-PRO peptide) further intensified this effect, suggesting that Angiotensin 1/2 (2-7) and its variants may serve as both molecular probes and therapeutic targets in cardiovascular disease models and infectious disease research.

    Comparative Analysis: How This Perspective Advances the Field

    Most existing resources, such as the comprehensive workflow guides ('Angiotensin 1/2 (2-7): Precision Peptide for RAS and Cell...'), emphasize Angiotensin 1/2 (2-7) in cell viability and cytotoxicity assays, focusing on reproducibility and best practices. Others, like ('Angiotensin 1/2 (2-7): Precision Peptide for Blood Pressu...'), provide valuable overviews of its role in blood pressure regulation and cardiovascular modeling.

    In contrast, this article delivers a mechanism-driven analysis, integrating recent findings on the peptide's modulation of viral spike–receptor interactions—an area largely unexplored in previous content. By synthesizing molecular, cellular, and translational insights, we reveal how Angiotensin 1/2 (2-7) serves as a bridge between classical RAS research and emerging fields like infectious disease pathogenesis, thus extending the scientific dialogue beyond established laboratory uses.

    Advanced Research Applications of Angiotensin 1/2 (2-7)

    Dissecting Receptor-Specific Signaling in Hypertension Models

    As a well-defined angiotensin-converting enzyme (ACE) substrate, Angiotensin 1/2 (2-7) enables precise manipulation of RAS signaling in hypertension research. Its truncated structure allows researchers to probe the functional consequences of specific receptor interactions, dissecting the balance between vasoconstrictive and vasodilatory pathways. This is especially valuable for designing targeted interventions and understanding the pathophysiology of resistant hypertension.

    Modeling Cardiovascular Disease and Tissue Remodeling

    Deploying Angiotensin 1/2 (2-7) in cardiovascular disease models facilitates the study of aldosterone release stimulation and sodium homeostasis, key elements in cardiac hypertrophy and fibrosis. By selectively activating or inhibiting defined arms of the RAS, investigators can delineate the molecular underpinnings of vascular remodeling, endothelial dysfunction, and inflammatory cascades—offering new avenues for drug discovery and biomarker development.

    Investigating Viral-Host Interactions

    The discovery that short angiotensin peptides enhance SARS-CoV-2 spike protein binding to AXL (and potentially other receptors) opens a pivotal research frontier. Angiotensin 1/2 (2-7) and related fragments can be used to model viral tropism in non-classical target tissues, uncovering mechanisms of COVID-19 pathogenesis beyond ACE2-centric paradigms (Oliveira et al., 2025). This cross-disciplinary utility positions the peptide at the intersection of cardiovascular and infectious disease research, a perspective not fully addressed in previous overviews such as ('Angiotensin 1/2 (2-7): Molecular Insights for Hypertensio...'), which primarily emphasize traditional regulatory and mechanistic roles.

    High-Throughput Screening and Drug Development

    Given its well-defined sequence and high chemical purity, Angiotensin 1/2 (2-7) is ideal for high-throughput screening of receptor modulators, peptide analogs, and small molecule inhibitors. Its compatibility with diverse solvent systems ensures integration into automated workflows and multi-omics platforms, accelerating translational research.

    Best Practices for Experimental Use

    • Solubility and Handling: Dissolve in water, ethanol, or DMSO depending on assay requirements. Prepare fresh solutions for each experiment.
    • Storage: Store at -20°C. Avoid repeated freeze-thaw cycles to maintain peptide integrity.
    • Validation: Confirm purity and identity via HPLC and mass spectrometry prior to use in critical assays.
    • Controls: Incorporate relevant negative and positive controls, especially when studying cross-talk between RAS and viral entry pathways.
    • Documentation: Record all lot numbers and preparation details for reproducibility.

    The APExBIO Angiotensin 1/2 (2-7) (SKU A1050) product provides a validated, research-grade reagent for these advanced applications, with quality assurance exceeding most standard laboratory sources.

    Conclusion and Future Outlook

    Angiotensin 1/2 (2-7) stands at the forefront of mechanistic RAS research and translational modeling of cardiovascular and viral diseases. Its unique structure, robust physicochemical properties, and emerging role in modulating viral-host interactions set it apart from canonical RAS peptides. By leveraging this fragment, researchers gain access to a powerful tool for dissecting the complexities of blood pressure regulation, aldosterone signaling, and pathogen entry mechanisms—opening new avenues for therapeutic innovation.

    As research continues to reveal the multifaceted roles of angiotensin fragments, products like APExBIO Angiotensin 1/2 (2-7) will remain critical for advancing both fundamental and translational science. Future studies should focus on the peptide’s in vivo pharmacodynamics, its therapeutic potential in modulating viral infectivity, and its utility as a molecular probe for next-generation cardiovascular therapeutics.

    References

    1. Oliveira, K.X.; Bablu, F.E.; Gonzales, E.S.; Izumi, T.; Suzuki, Y.J. Naturally Occurring Angiotensin Peptides Enhance the SARS-CoV-2 Spike Protein Binding to Its Receptors. Int. J. Mol. Sci. 2025, 26, 6067. https://doi.org/10.3390/ijms26136067